Curious to see your top suppliers emissions?
Book a demo for a pilot project
RedHill Biopharma Ltd.
Pharmaceutical Preparation ManufacturingIsrael
Last verified 10 months agoredhillbio.com
RedHill Biopharma Ltd., a prominent biopharmaceutical company headquartered in Israel, focuses on the development and commercialisation of innovative therapies for gastrointestinal diseases and cancer. Founded in 2009, RedHill has made significant strides in the industry, particularly with its core products, which include advanced treatments that leverage unique mechanisms of action to address unmet medical needs.
With a strong presence in both the Israeli and international markets, RedHill has established itself as a leader in the biopharma sector. The company’s commitment to research and development has led to notable achievements, including successful clinical trials and strategic partnerships that enhance its market position. RedHill Biopharma continues to push the boundaries of medical science, aiming to improve patient outcomes through its cutting-edge therapies.
23
DitchCarbon score
-17 vs industry average
RedHill Biopharma Ltd.’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at RedHill Biopharma Ltd.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for RedHill Biopharma Ltd. yet.
RedHill Biopharma Ltd.'s reported carbon emissions
RedHill Biopharma Ltd., headquartered in Israel (IL), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time.
As there are no emissions data or reduction initiatives available, it is unclear how RedHill Biopharma Ltd. aligns with industry standards for climate action. The absence of emissions reporting may reflect a broader trend within the biopharmaceutical sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious targets for carbon reduction.
In summary, RedHill Biopharma Ltd. has not provided emissions data or climate commitments, indicating a potential area for future development in their sustainability strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
RedHill Biopharma Ltd.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for RedHill Biopharma Ltd. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
RedHill Biopharma Ltd.10 months ago
23
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more